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Background: Recent studies have described relationships between iron status and fibroblast growth factor-23
(FGF23) but the possible confounding effects of inflammation on iron status have not been considered. The aims of
this study were a) to consider a relationship between FGF23 and inflammation b) to identify relationships between
iron status and FGF23 whilst correcting for inflammation and c) to assess the relationship between changes in
FGF23 and iron status after supplementation.
Study design and methodology: Blood samples from an iron supplementation study in children (n=79) were
collected at baseline and after 3 months supplementation with iron sulphate. The children were from a rural
Gambian population where rates of iron deficiency and infection/inflammation are high. This study identified
cross-sectional and longitudinal relationships between FGF23, inflammation (C-reactive protein (CRP)) and iron
status (ferritin, haemoglobin, and zinc protoporphyrin). CRP ≥ 5 mg/dL was used to indicate inflammation and
FGF23 ≥ 125 RU/mL was considered elevated.
Results: FGF23 was not significantly correlated with CRP. At baseline, all markers of iron status were significantly
correlated with FGF23. Ferritin was the strongest independent inverse predictor of FGF23 in subjects with and without
elevated CRP (coefficient (SE)): All subjects=−0.57 (0.12), R2=22.3%, P≤0.0001; subjects with CRP < 5 mg/dL=−0.89 (0.14),
R2=38.9%, P≤0.0001. FGF23 was elevated in 28% of children at baseline and 16% post supplementation (P=0.1).
Improved iron status was associated with a decrease in FGF23 concentration in univariate (ferritin =−0.41 (0.11),
R2=14.1%, P=0.0004; haemoglobin=−2.22 (0.64), R2=12.5%, P=0.0008; zinc protoporphyrin=1.12 (0.26), R2=18.6%,
P≤0.0001) and multivariate analysis (R2=33.1%; ferritin=−0.36 (0.10), P=0.0007, haemoglobin = −1.83 (0.61), P=0.004, zinc
protoporphyrin=0.62 (0.26), P=0.02).
Conclusions: Iron status rather than inflammation is a negative predictor of plasma FGF23 concentration. Improvements
in iron status following iron supplementation are associated with a significant decrease in FGF23 concentration.
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Fibroblast growth factor-23 (FGF23) is a bone derived,
phosphate regulating hormone which is often elevated
in genetic hypophosphataemic disorders [1] and in
chronic kidney disease [2]. Recent studies have identi-
fied relationships between FGF23 and various markers
of iron status. These include an inverse correlation* Correspondence: Vickie.braithwaite@mrc-hnr.cam.ac.uk
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distribution, and reproduction in any mediumbetween FGF23 and serum iron (Fe) [3,4], haemoglobin
(Hb) [5], and ferritin (Ferr) [6]. However each of these
markers of iron status is affected by the acute phase re-
sponse and consequently they have limited use as mar-
kers of nutritional iron status when used in isolation
from markers of inflammation [7]. It is plausible that
the inverse correlation between markers of iron status
and FGF23 [3-6] is the result of confounding by the in-
flammatory response. The potential role of the inflam-
matory response in FGF23 pathways has not yet been
considered [8].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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ship between FGF23 and inflammation b) to identify
relationships between iron and FGF23 whilst correcting
for inflammation and c) to assess the change of FGF23
after supplementation with iron. The study used data
from children in a rural Gambian population where diet-
ary calcium intakes are low, rates of iron deficiency [9]
and infection are high, and where a wide range of
FGF23 concentrations have been reported [5].
Methods
Subjects and study information
A subset of samples (n=79) from a cohort of children
(n=821) who participated in a non-controlled iron sup-
plementation study designed to assess the variability of
response to supplementation during the malaria season
were included in this study. The children in the cohort
were recruited from the local community in West
Kiang, The Gambia and were aged between 0.5-7.0 y.
Baseline measurements and start of supplementation
were conducted in August 2004 and post supplementa-
tion measurements were conducted in December 2004
[10]. Subjects were given Fe 6x/week for three months
in the form of Fe sulphate tablets (Nutriset, Malaunay,
France). Daily consumption of the supplement was
supervised by trained fieldworkers. The dose given was
dependent on age and, if present, the severity of base-
line anaemia (<7 g/dL): 25 mg elemental Fe in 76 sub-
jects and 50 mg in 3 severely anaemic subjects. A
blood sample and anthropometric data were collected
at both time-points. All samples from subjects aged be-
tween 4.8–6.0 y with sufficient residual EDTA-plasma
stored from samples at the beginning and end of sup-
plementation (n=79, 47 female/32 male) were included
in this study and analysed for plasma FGF23. The mean
(SD) time from measurements at baseline to post sup-
plementation was 118 (2) days.
Ethical statement
Ethical approval from The Gambian Government/MRC
Laboratories Joint Ethics Committee for the original iron
supplementation trial (n=821) and the subset study
(n=79) was obtained. Written informed consent from
the parents of the children involved were obtained for
both the original iron supplementation trial and for any
further analyses performed on stored samples.
Anthropometry
Weight was measured (kg) using a calibrated electronic
scale (model HD-314, Tanita B.V., Hoofddorp, The
Netherlands). Height was measured (cm) using a port-
able stadiometer (Leicester Height Measure, Seca
GmbH & Co., Hamburg, Germany). Body mass index
(BMI) was calculated (kg/m2).Fasting blood samples
In the original study an overnight fasting, venous blood
sample had been collected into lithium-heparin (LiHep)
and EDTA coated tubes. Fresh blood had been used to
measure Hb by haemoglobinometer (Medonic CA, 530
Oden 16 Parameter System) and zinc protoporphyrin
(ZnPP) by haematofluorimeter (Aviv Biomedical Lake-
wood, NJ). The remainder of the blood had been sepa-
rated by centrifugation at 4°C and frozen at −70°C, and
had been later transported frozen on dry ice to MRC
Human Nutrition Research (HNR), Cambridge, UK
where it had been stored at −80°C until analysis. Ferr
and CRP had been measured in LiHep by Immunoassay
(Abbot Laboratories, IL, USA and Dade DimensionW, re-
spectively) [10]. For the purpose of this study, the re-
sidual, frozen EDTA samples were analysed for FGF23
using a 2nd generation C-terminal, two-site enzyme-
linked immunosorbent assay (Immutopics Inc., Ca,
USA). Assay accuracy and precision were monitored
using kit controls supplied by the manufacturer.
Statistical analysis
All statistical analyses were performed using DataDesk
6.1 (Data Description Inc., NY, USA) with the exception
of two-tailed Chi-square tests (without Yates’ correction)
which were performed using GraphPad QuickCalcs
(GraphPad Software, Inc., CA, USA). Normally distribu-
ted data are presented as mean (1SD), positively skewed
distributions of data are presented as geometric mean
(−1SD, +1SD) obtained from the antilog of mean (−1SD,
+1SD) of the logged values. Variables with positively
skewed distributions were transformed to natural loga-
rithms before further statistical analysis. Paired t-tests
were used to assess the significance of change in an-
thropometric and biochemical variables from baseline
and after supplementation.
A regression model was used with loge FGF23 as the in-
dependent variable. Age was not significantly correlated
with any of the biochemical variables and was therefore
not adjusted for in the regression model. CRP ≥ 5 mg/dL
was used to indicate the presence of inflammation [11]
and an upper-limit of ≥ 125 RU/mL, as defined by the
manufacturers, was used for FGF23. Subjects were
defined as being anaemic according to WHO guidelines:
Hb ≤ 11.0 g/dL for < 4.99 y, and ≤ 11.5 g/dL for 5–12 y
[7,11]. Subjects with Ferr < 15 ng/mL were considered
low [11]. Selectors for CRP < 5 and ≥ 5 mg/dL were used
in regression analysis. Relative change (Δ) in variables (X)
over time was calculated by: ΔX = logeXpost - logeXpre. Uni-
variate analyses were conducted to determine the relation-
ships between ΔFGF23 as the dependent variable, with Δ
in Ferr, Hb and ZnPP in turn. Multivariate analysis was
conducted to determine the relationship between ΔFGF23
as the dependent variable, and Δ in the three markers of
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coefficient (SE).
Results
At baseline the mean age of the subjects was 5.5 (0.3) y,
28% had elevated FGF23, 87% were anaemic, 24% had
low Ferr, and 13% had a CRP ≥ 5 mg/dL. After supple-
mentation, the prevalence of elevated FGF23 was 16%
(P=0.1), the prevalence of anaemia had decreased to 62%
(P=0.0005), there were no subjects with low Ferr
(P≤0.0001) and the frequency of subjects with CRP ≥ 5
mg/dL did not significantly change (P=1.0).
After supplementation both Hb and Ferr had signifi-
cantly increased from baseline (Hb (g/dL) from 10.3
(1.3) to 11.3 (1.0) P≤0.0001; Ferr (ng/mL) from 26.6
(12.3, 57.6) to 46.9 (28.6, 76.9) P≤0.0001). ZnPP (μmol/
mol haem) significantly decreased by the end of supple-
mentation (from 61.9 (32.4, 118.3) to 24.7 (15.8, 38.5),
P≤0.0001). Mean FGF23 concentration had not signifi-
cantly changed from baseline to after supplementation
(from 96.0 (38.4, 240.4) to 82.8 (47.1, 145.7) RU/mL,
P=0.1) (Table 1); although there was a wide range of
changes observed (mean (−1SD, +1SD) change in
FGF23 = 16.2 (4.6, 56.9) RU/mL).
There was no correlation between FGF23 and CRP at
baseline (coefficient (SE)=-0.01 (0.11), R2=−1.3%, P=0.9)
or at the end of supplementation (0.11 (0.07), R2=1.8%,
P=0.1).
At baseline, FGF23 was significantly correlated with all
markers of iron status. Ferr was the strongest, independ-
ent predictor of FGF23 in loge-loge models (−0.57 (0.12),
R2=22.3%, P≤0.0001). When excluding subjects with
CRP ≥ 5 mg/dL, the relationship between FGF23 andTable 1 Anthropometric and biochemical variables at
baseline and after iron supplementation
Dependent Baseline After
supplementation
Paired t-test
Variable n= 79 n= 79 P-Value
Age (y) 5.48 (0.32) 5.81 (0.32) -
Sex (F/M) 47/32 47/32 -
Height (cm) 105.6 (6.8) 107.7 (6.5) ≤0.0001
Weight (kg) 15.6 (2.2) 16.3 (2.2) ≤0.0001
BMI (kg/m2) 13.9 (1.2) 14.0 (1.2) 0.2
ZnPP (μmol/
mol haem)*
61.9 (32.4, 118.3) 24.7 (15.8, 38.5) ≤0.0001
Hb (g/dL) 10.3 (1.3) 11.3 (1.0) ≤0.0001
Ferr (ng/mL)* 26.6 (12.3, 57.6) 46.9 (28.6, 76.9) ≤0.0001
FGF23 (RU/mL)* 96.0 (38.4, 240.4) 82.8 (47.1, 145.7) 0.1
CRP (mg/dL)* 2.45 (1.00, 6.01) 1.99 (0.83, 4.78) 0.1
Data shown as mean (SD) or geometric mean (−1SD, +1SD) for skewed
variables (*).Ferr strengthened (−0.89 (0.14), R2=38.9%, P≤0.0001)
(Figure 1).
The ΔFGF23 was significantly negatively correlated
with Δ in markers of iron status in univariate (Ferr = - 0.41
(0.11), R2=14.1%, P = 0.0004, Hb=−2.22 (0.64), R2=12.5%,
P = 0.0008 and ZnPP = 1.12 (0.26), R2 = 18.6%, P ≤
0.0001) analysis. In multivariate analysis, Δ in all three
markers of iron status predicted R2 = 33.1% of the vari-
ation of ΔFGF23 (Ferr = - 0.36 (0.10), P = 0.0007, Hb =
−1.83 (0.61), P = 0.004, ZnPP = 0.62 (0.26), P = 0.02).
Discussion
This study has shown the existence of elevated FGF23,
both before and at the end of iron supplementation
(28% and 16% respectively) in apparently healthy, al-
though generally undernourished children. This rate is
in keeping with previous prevalence findings in Gambian
children of similar age [5].
In this study, we have used a combination of iron sta-
tus markers coupled with CRP, an acute phase marker
[11], to provide further evidence of an inverse relation-
ship between FGF23 and iron status.
In keeping with previous reports [9], ~90% of children
in this study were anaemic at baseline. Overall Hb con-
centration increased after supplementation, although
~60% of children were still defined as anaemic [11]. Fur-
thermore, after supplementation the concentration of
the other markers of iron status, namely Ferr and ZnPP,
changed sufficiently to indicate that the cohort had
improved iron status.
Although CRP was not a significant predictor of
FGF23, the association between FGF23 and Ferr was fur-
ther strengthened when children with a raised CRP were
removed from the regression model (R2=38.9%,
P≤0.0001). All of the iron status markers were independ-
ently correlated with FGF23 at baseline and Ferr was the
strongest predictor of FGF23 concentration (R2=22.3%,
P≤0.0001). In addition the decrease in FGF23 concentra-
tion was significantly correlated with the improvement
of all of iron status markers (both in univariate and
multivariate analyses) during the period of iron supple-
mentation. A point to note is that due to the wide range
of FGF23 concentrations within subjects the decrease in
mean FGF23 concentrations after supplementation com-
pared with baseline was not statistically significant
(P=0.1).
Although a causal relationship cannot be established,
this study shows that FGF23 concentration decreased
when iron status improved. This differs from a previous
report which described an increase in FGF23 concentra-
tion in response of intravenous iron therapy in patients
with iron deficiency anaemia and normal baseline
FGF23 concentrations [12] but is in keeping with the ob-
servation that poor iron status was associated with
A B
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Figure 1 Cross-sectional and longitudinal relationships between plasma FGF23 with markers of iron status. Relationship between plasma
FGF23 and markers of iron status at baseline (A) where subjects are divided by CRP and with change (Δ) overtime (B-D.) where ΔX = log eXpost −
log eXpre The equations of the line for A: Subjects with CRP<5 mg/dL = ▲: logeFGF23 = [7.32 (SE 0.44)] - [0.89 (SE 0.14) (logeFerr)], R
2=38.9%,
P≤0.0001. Subjects with CRP≥ 5 mg/dL = ∇ : logeFGF23 = [2.60 (SE 1. 83)] + [0.39 (SE 0.42)(logeFerr)], R
2=−1.0%, P=0.4. All subjects together = :
logeFGF23 = [6.44 (SE 0.39)] - [0.57 (SE 0.12) (logeFerr)], R
2=22.3%, P≤0.0001. B: ΔFGF23 = [0.08 (SE 0.11)] − [0.41 (SE 0.11)(ΔFerritin)], R2=14.1%,
P=0.0004. C: ΔFGF23 = [0.07 (SE 0.11)] − [2.22 (SE 0.64)(ΔHaemoglobin)], R2=12.5%, P =0.0008. D: ΔFGF23 = [0.76 (SE 0.22)] + [1.12 (SE 0.26)
(ΔZinc protoporphyrin)], R2=18.6%, P≤0.0001.
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adults [6]. It has been suggested that low iron may result
in an increased rate of proteolytic cleavage of the intact
and biologically active hormone to inactive C- and N-
terminal fragments. However, recent western-blotting
analysis of plasma from Gambian children has not pro-
vided any evidence in support of this [13].
In light of this, the more plausible scenario is that
iron is involved in the expression and/or secretion of
FGF23 rather than having effects on the degradation
pathway. This scenario could be further substan-
tiated through the use of the intact FGF23 assay.
Unfortunately, the intact FGF23 assay was not avail-
able for use in this study.A limitation of this study is that there was no control
group as all subjects were iron supplemented as part of
the original study. Therefore, changes seen in FGF23
may not be attributable to the supplementation. Another
limitation of this study is that only one marker of in-
flammation was measured and CRP is a marker of acute
rather than chronic inflammation.Conclusion
In conclusion this study has demonstrated that FGF23
concentration is not correlated with inflammation but is
negatively correlated with markers of iron status. Fur-
thermore an improvement in iron status, associated with
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deficiency, is associated with a decrease in plasma FGF23.
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